Search

INSTITUTE OF HEALTH OF EMPLOYEES OF THE STATE OF CEARA, Brazil has invited tenders for Medication for Adjuvant Chemotherapy Treatment.. Tender Notice No: 2024/18683 Deadline: August 5, 2024 Copyright © [...]

MINISTRY OF HEALTH AND WELFARE TAICHUNG HOSPITAL, Taiwan has invited tenders for Temporary Purchase of Drugs for Adjuvant Therapy for Breast Cancer. Tender Notice No: TH113097 Deadline: July 1, 2024 [...]

MINISTRY OF HEALTH AND WELFARE TAICHUNG HOSPITAL, Taiwan has invited tenders for Temporary Purchase of Drugs for Adjuvant Therapy for Breast Cancer. Tender Notice No: TH113097 Deadline: June 18, 2024 [...]

The patient’s exceptional recovery was the result of a comprehensive treatment approach that included neoadjuvant chemotherapy, nivolumab immunotherapy, and minimally invasive thoracic surgery. Abu Dhabi-UAE. The Abu Dhabi Health Services [...]

Estonia based Ou Antegenes has secured contract from sihtasutus Pohja-Eesti Regionaalhaigla for Laboratory Services - a test to define the optimal adjuvant therapy of breast cancer. The value of the [...]

Special notice (original): an11--precision neoadjuvant therapy for high risk localized prostate cancer with pten loss merit review for clinical trials award number i01 cx002517-01 notice of intent to award a [...]

Gurgaon, May 30 -- Art of Healing Cancer (AOHC), celebrated as one of the most advanced institutions pioneering precision oncology for effective patient treatment, shares crucial insights into the transformative [...]

AstraZenecas Tagrisso (osimertinib) has been approved in Japan for the adjuvant treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery. This approval by [...]

Anti-PD-L1 antibody Tecentriq obtains manufacturing and marketing approval as postoperative adjuvant therapy for PD-L1-positive non-small cell lung cancer The first cancer immunotherapy to show efficacy in a global phase III [...]

If approved, the Opdivo regimen would be the first and only immunotherapy-based option authorized for use before surgery in patients with non-small cell lung cancer ( NSCLC) in the European [...]

Further positive results from the OlympiA Phase III trial showed AstraZeneca and MSDs Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in [...]

First and Only Targeted Adjuvant Therapy With FDA-Approved Indication Specifically for Patients With gBRCAm, HER2-Negative High-Risk Early Breast Cancer First and Only PARP Inhibitor to Show Overall Survival Benefit in [...]

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks for three [...]

Application based on CheckMate -816, the first Phase 3 trial with an immunotherapy-based combination to demonstrate improved event-free survival and pathologic complete response in this setting If approved, Opdivo plus [...]

New agreement to utilize AI to predict the response of neoadjuvant therapy Egypt: GE Healthcare and Baheya Foundation recently announced a partnership to develop and validate the use of Artificial [...]

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that a supplemental New Drug Application (sNDA) for LYNPARZAhas been accepted and granted priority review by the [...]

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting Approval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival [...]

Oncologists, surgeons, and specialists surveyed cite long-term survival, prevention of relapse or recurrence and quality of life as most important factors when making treatment decisions before and/or after surgery Results [...]

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer New data from the phase III [...]

The U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation. [...]

The new adjuvant use for Opdivo (nivolumab) is for patients with urothelial carcinoma (UC) the most common form of bladder cancer who have had their cancer treated with surgery but [...]

Application is being reviewed under the US FDAs Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved [...]

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the companys supplemental Biologics License Application (sBLA) and granted Priority Review for [...]

(GlobeNewswire) - Application is being reviewed under the US FDAs Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant [...]

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the companys supplemental Biologics License Application [...]

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer [...]

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer who have residual [...]

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Mercks anti-PD-1 therapy, for the treatment of [...]

Merck, known as MSD outside the United States and Canada, announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant Phase 3 study KEYNOTE-522. The trial investigated neoadjuvant KEYTRUDA, Mercks [...]

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant Phase 3 study KEYNOTE-522. The trial investigated [...]

For the first time as cancer immunotherapy, it is effective in postoperative adjuvant therapy for non-small cell lung cancer Application based on the results of Phase III clinical trial IMpower [...]

(GlobeNewswire) - Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to [...]

Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as [...]

First Medicine Specifically Targeting BRCA Mutations to Demonstrate Statistically Significant Improvement in Invasive Disease-Free Survival in Adjuvant Setting Following Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy AstraZeneca and Merck, [...]

Irvine, June 5 -- Whole transcriptome analysis of ER+ breast cancers showed no substantial difference in gene expression between tumors from women younger than 50 and women older than 50 [...]

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ('Kintara' or the 'Company'), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient [...]

The adoption of Roches Tecentriq (atezolizumab) as an adjuvant treatment in non-small cell lung cancer (NSCLC) is unlikely without a survival improvement, most experts said, despite the Phase III IMpower010 [...]

The therapeutic has been approved as an adjuvant treatment for varieties of esophageal cancers in patients who have received neoadjuvant chemoradiotherapy. Bristol Myers Squibb (BMS) announced the US Food and [...]

Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80% AstraZenecas Tagrisso (osimertinib) has been approved in [...]

AstraZeneca PLC (LON:AZN) said Tagrisso has been approved in the EU for the adjuvant treatment of adult patients with a type of early-stage lung cancer. It targets epidermal growth factor [...]

The EC approval is based on results from the Phase III ADAURA trial, within which adjuvant treatment with Tagrisso reduced the risk of disease recurrence or death by 83% in [...]

For years, standard treatment for patients with stage III colon cancer has been adjuvant chemotherapy for 6 months following resection. Researchers designed the IDEA (International Duration Evaluation of Adjuvant therapy) [...]

Immunotherapeutic drugs, as represented by immune-checkpoint blockade (ICB), have achieved tremendous success in curing various tumors in recent years, thus improving the survival and life quality of some tumor patients [...]

(GlobeNewswire) - Tecentriq improved disease-free survival by more than one-third in people with PD-L1-positive resectable early-stage lung cancer, compared with best supportive care First and only cancer immunotherapy to show [...]

Tecentriq improved disease-free survival by more than one-third in people with PD-L1-positive resectable early-stage lung cancer, compared with best supportive care First and only cancer immunotherapy to show positive Phase [...]

- Opinion based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80% AstraZenecas Tagrisso (osimertinib) has been recommended [...]

(GlobeNewswire) - Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative [...]

Tagrisso is the only targeted medicine to show efficacy in the treatment of early-stage lung cancer in a global trial and the first such medicine approved in China Approval based [...]

(GlobeNewswire) - Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to [...]

(GlobeNewswire) - Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, [...]